HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chabriat, H. Articles by Samson, Y. Search for Related Content PubMed PubMed Citation Articles by Chabriat, H. Articles by Samson, Y.

In-Vivo SPECT Imaging of D2 Receptor with, Iodine-Iodolisuride: Results in Supranuclear Palsy

Service Hospitalier Frédéric Joliot, C.E.A., DRIPP, Orsay, France
Clinique des Maladies du Sysème Nerveux and Clinique de Neurologie et de Neuropsychologie, Hôpital La Salpêtrière, Paris, France
INSERM U334, C.E.A, DRIPP, Orsay, France

Correspondence: For reprints contact: Dr. Chabriat, Service Hospitalier Frédéric Joliot, CEA, 4 Place du Général Leclerc, 91406 Orsay, France.

ABSTRACT

We assessed the potential use of [¹²³I]iodolisuride (ILlS), a new iodine ergolene derivative, to study human striatal D2 dopamine receptors with SPECT. In normal subjects, we found that the tracer accumulated preferentially in striatum. This was prevented by high doses of haloperidol. The striatal accumulation was maximal between 60 and 180 min after injection. The striatum-to-cerebellum radioactivity concentration ratio as an index of specific binding, measured 60 min after injection, was 1.52±0.19 (mean ± s.d.) in controls and 1.36 ± 0.11 in patients with supranuclear palsy (p < 0.03). Our results show that ILIS may be used to study D2 receptors with SPECT. In-vivo changes of D2 receptors in human brain may be detected with this method.